PRPascal Richette

Pascal Richette

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pascal Richette has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol

    by Pascal Richette, Thomas Bardin

    Ature Clinical Practice Oncology will deliver timely interpretations of key research developments, translating the latest findings into clinical practice. Our Editor-in-Chief and international Advisory Board will ensure comprehensive coverage of topical issues throughout the year, with the highest standards of editorial quality and integrity that are hallmarks of Nature Publishing Group.


    • 1 December 2005
      • Vol. 32  (12) , 2434-6

    Hypomagnesemia and chondrocalcinosis in short bowel syndrome.

    by Pascal Richette, Ghazi Ayoub, Thomas Bardin, Sophie Bouvet, Philippe Orcel, Abdul-Monem Badran

    Chondrocalcinosis is a result of deposition of calcium pyrophosphate dihydrate (CPPD) crystals in cartilage and fibrocartilage. Chondrocalcinosis is usually sporadic but has also been associated with a variety of metabolic diseases including hypomagnesemia. Reported cases of hypomagnesemia associated chondrocalcinosis were mostly due to renal genetic disorders such as Bartter's or Gitelman's syndrome. We describe 3 patients with chronic hypomagnesemia induced by short bowel syndrome who developed symptomatic chondrocalcinosis. CPPD crystals were identified by polarizing light microscopy in one patient. The underlying intestinal pathology was radiation enteritis in 2 patients and mesenteric arterial thrombosis in the third. Our observations strengthen the hypothesis of a role for magnesium in CPPD crystal deposition disease.


    • 1 October 2004
      • Vol. 31  (10) , 2079-81

    Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis.

    by Pascal Richette, Philippe Dieudé, Joël Damiano, Frédéric Lioté, Philippe Orcel, Thomas Bardin

    We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom infliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other.


  • Open Access

    Dual effects of 17β-oestradiol on interleukin 1β-induced proteoglycan degradation in chondrocytes

    by P Richette, M F Dumontier, M François, L Tsagris, C Korwin-Zmijowska, F Rannou, M T Corvol

    Objective: To determine whether 17β-oestradiol (E2) modulates interleukin (IL) 1β-induced proteoglycan degradation in chondrocytes, and to analyse the part played by metalloproteinases (MMPs) in this process. Methods: Primary cultured rabbit articular chondrocytes were prepared and treated with 10 ng/ml IL1β combined or not with 0.1–10 nM E2. Neosynthesised proteoglycans (PGs) were evaluated after incorporation of [35SO4]sulphate and further analysed after chromatography on a Sepharose 2B column. Chondrocyte mRNA levels of aggrecan, MMP-1, -3, -13, and tissue inhibitor of metalloproteinase-1 (TIMP-1) were studied by northern blot. MMP-1 activity was measured by zymography. MMP-1 gene transcription was studied by transient transfection of chondrocytes with an MMP-1-luciferase construct. Results: E2 modulated the IL1β-induced total sulphated PGs in rabbit articular chondrocytes, which decreased as the E2 concentration was increased. At a low concentration (0.1 nmol/l) E2 counteracts the IL1β-induced decrease in sulphated PG, while at high concentration (10 nmol/l) E2 enhances the IL1β effects. A biphasic E2 effect was also observed on IL1β-induced disaggregation of PG, 53–58 kDa gelatinolytic activity, and MMP-1, -3, and -13 mRNA levels. In contrast, E2 did not modify the level of aggrecan mRNA and had no effect on TIMP-1 mRNA expression. Finally, simultaneous addition of IL1β and E2 (0.1–10 nmol/l) did not modify IL1β-induced MMP-1-luciferase activity, suggesting that E2 effects probably occur at the post-transcriptional level of MMP gene expression. Conclusion: Oestrogen concentration may have an inverse effect on IL1β stimulated proteoglycan degradation and MMP production by chondrocytes.


  • Estrogens, cartilage, and osteoarthritis

    by Pascal Richette, Maïté Corvol, Thomas Bardin